Urogen Pharma Ltd (NASDAQ:URGN) has been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $71.75.
A number of research firms have recently commented on URGN. Zacks Investment Research raised Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 17th. Jefferies Financial Group began coverage on Urogen Pharma in a report on Thursday, November 8th. They set a “buy” rating and a $77.00 price target for the company. Oppenheimer set a $75.00 price target on Urogen Pharma and gave the stock a “buy” rating in a report on Tuesday, November 13th. Stifel Nicolaus initiated coverage on Urogen Pharma in a report on Thursday, September 13th. They issued a “buy” rating and a $70.00 target price for the company. Finally, Cowen reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Tuesday, August 14th.
Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. acquired a new position in Urogen Pharma in the 3rd quarter worth about $119,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Urogen Pharma in the 2nd quarter worth about $129,000. UBS Group AG increased its holdings in Urogen Pharma by 31.5% in the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock worth $180,000 after purchasing an additional 865 shares in the last quarter. Rothschild Investment Corp IL acquired a new position in Urogen Pharma in the 3rd quarter worth about $201,000. Finally, WINTON GROUP Ltd acquired a new position in Urogen Pharma in the 3rd quarter worth about $221,000. 70.41% of the stock is owned by institutional investors and hedge funds.
Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Thursday, November 15th. The company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). Urogen Pharma had a negative return on equity of 61.06% and a negative net margin of 4,296.08%. The business had revenue of $0.28 million for the quarter. As a group, research analysts anticipate that Urogen Pharma will post -4.47 earnings per share for the current year.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More: How to Use a Moving Average for Trading
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.